Brontictuzumab

Drug Profile

Brontictuzumab

Alternative Names: Anti-Notch 1; Anti-Notch 1 monoclonal antibody; OMP-52M51

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer OncoMed Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Notch-1 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Clinical Phase Unknown Adenocarcinoma
  • Discontinued Haematological malignancies

Most Recent Events

  • 22 Jul 2016 Phase-I development is ongoing for Solid tumours in USA (NCT01778439; OncoMed Pharmaceuticals pipeline, July 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 01 Jul 2016 OncoMed Pharmaceuticals completes a phase I trial in Solid tumours (Treatment-resistant, Second-line therapy or greater) in USA (NCT01778439)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top